FDA Approves First Treatment for Advanced Form of the Second Most Common Skin Cancer
The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. This is the first FDA approval of a drug specifically for advanced….
Full Text: PDF
LumiText Publishing, P.O. Box 774, Ellicott City, MD 21041
Copyright © 2008 LumiText Publishing. All rights reserved.